Finally, higher inhibitory abilities of the anti-MET BpAb in comparison to the parental mAbs (WT46 and WT52) were shown in vitro using functional cell-based assays and more importantly in vivo using a xenograft mouse model, in which the inhibition of the tumor progression was observed after low administered doses of anti-MET Abs (0.5 mg/kg, Fig. 6c). This evidence concerns the gene MET and neoplasm.